Sept 22 (Reuters) - Amgen (AMGN.O) said on Tuesday its experimental drug to treat an autoimmune disease that attacks the body’s moisture-producing glands met the main goal of reducing disease activity in a late-stage trial.

9 月 22 日（路透社）- 安進（AMGN.O）週二表示，其用於治療一種攻擊人體分泌腺體的自身免疫性疾病的實驗性藥物，在後期臨牀試驗中達到了降低疾病活動度的主要目標。

Here are some details:

以下是部分細節：

The drug dazodalibep showed statistically significant and clinically meaningful improvement in patients with Sjogren’s disease at week 48.

藥物 dazodalibep 在第 48 周時，使乾燥綜合徵患者的病情出現了具有統計學意義且具臨牀意義的改善。

Sjogren’s disease can cause extensive dryness of the eyes, mouth and other parts of the body, along with fatigue and chronic pain.

乾燥綜合徵可能導致眼睛、口腔及身體其他部位嚴重乾燥，並伴有疲勞和慢性疼痛。

It affects about 1% of the global population and predominantly affects women, according to the National Institutes of Health.

據美國國立衞生研究院稱，該病影響全球約 1% 的人口，且主要影響女性。

Amgen said most adverse events in the trial were mild to moderate, with few patients discontinuing treatment.

安進表示，試驗中的大多數不良事件為輕度至中度，僅有少數患者停止治療。

Novartis (NOVN.S) and Johnson & Johnson (JNJ.N) are also developing drugs to treat Sjogren’s disease, which has no approved treatments in the US.

諾華（NOVN.S）和強生（JNJ.N）也在開發用於治療乾燥綜合徵的藥物，目前美國尚無針對該病的獲批療法。

Amgen plans to present detailed data from the trial at an upcoming medical meeting. The trial is expected to be completed in the fourth quarter of 2026.

安進計劃在即將召開的醫學會議上公佈該試驗的詳細數據。該試驗預計將於 2026 年第四季度完成。